University of Munster   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Munster Germany (1780)

Organization Overview

First Clinical Trial
1992
NCT00002516
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Children`s Medical Hospital, University of Muenster, Muenster, Germany | Department of Anesthesia and Intensiv Care, University Hospital Muenster | Department of Anesthesia and Intensive Care, University Hospital Muenster | Department of Anesthesiology and Intensive Care, University Hospital Muenster | Department of Dermatology, University Hospital Muenster | Department of Dermatology, University Hospital Muenster, Muenster, Germany | Department of Neurology, University Hospital of Muenster, Germany | Department of Nuclear Medicine, University Hospital Muenster | Dept. of Neurology, Universityclinic of Muenster | Dept. of Neurology, University Hospital Muenster | Dept. of Neurology, University Hospital Muenster, Germany | Dept. of Neurology, University of Muenster, Germany | Dept. of Ophthalmology, University of Muenster Medical Center | Dermatology, Univ. of Muenster, Germany | dr. J.M. Munster, gynaecologist, principal investigator | IZKF (Interdisciplinary Centre for Clinical Research (IZKF), Muenster) | Muenster University Hospital | Neurology, University of Muenster, Germany | Univeristy Hospital Muenster | Universitatsklinikum Munster | Universitätsklinikum Münster | Universitätsklinikum Münster Klinik für Hautkrankheiten Zentrale Studienkoordination für innovative Dermaologie (ZID) | Universitätsklinikum Münster, Klinik für Urologie und Kinderurologie | University Clinics Muenster, Germany | University Hospital Muenster | University Hospital Muenster, Dept. of Anesthesiology | University Hospital Muenster, Dept. of Anesthesiology, Intensive Care Medicine and Pain Therapy | University Hospital Muenster, Dept. of Anesthesiology, Intensive Care Therapy and Pain Medicine | University Hospital Muenster, Dept. of Periodontology | University Hospital Muenster, Klinik für Kinder- und Jugendmedizin - Pädiatrische Hämatologie und Onkologie | University Hospital Muenster, Klinik und Poliklinik für Neurochirurgie | University Hospital Muenster, University of Muenster | University Hospital Munster, Germany | University Hospital of Muenster | University Hospital of Muenster, Institute of Medical Microbiology | University Hospital of Muenster, KMT Center | University of Muenster, Germany | University of Muenster, Medical Center, Department of Medicine, Hematology and Oncology | University of Münster | Universtiy hospital Muenster, MedD | Westfälische Wilhelms-Universität Münster

Active Ingredients

Drugs in Phase 4 Trials (48)

alemtuzumab (campath) (1 trial)

atorvastatin (lipitor) (1 trial)

benzalkonium (1 trial)

benzocaine (1 trial)

carboplatin (paraplatin) (2 trials)

cisplatin (platinol) (1 trial)

citrasate (1 trial)

clozapine (clozaril) (1 trial)

darbepoetin alfa (aranesp) (1 trial)

dimethyl fumarate (tecfidera) (1 trial)

dopamine (intropin) (1 trial)

duloxetine (Cymbalta) (1 trial)

escitalopram (lexapro) (1 trial)

esketamine (spravato) (1 trial)

etoposide (vepesid) (5 trials)

ferric carboxymaltose (Injectafer) (1 trial)

ferrous fumarate (1 trial)

fingolimod (gilenya) (1 trial)

gemfibrozil (lopid) (1 trial)

heparin (liquaemin) (1 trial)

hyaluronic acid (1 trial)

ifosfamide (ifex) (5 trials)

lamotrigine (lamictal) (1 trial)

levodopa (larodopa) (5 trials)

lithium (lithonate) (1 trial)

magnesium chloride (1 trial)

metronidazole (flagyl) (1 trial)

modafinil (provigil) (1 trial)

mupirocin (bactroban) (1 trial)

mycophenolate (myfortic) (5 trials)

natalizumab (tysabri) (1 trial)

pentastarch (Pentaspan) (1 trial)

pergolide (permax) (1 trial)

potassium chloride (klor-con) (1 trial)

pramipexole (mirapex) (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

quetiapine (seroquel) (2 trials)

ranibizumab (lucentis) (1 trial)

rivastigmine (exelon) (2 trials)

sertraline (zoloft) (1 trial)

sirolimus (rapamune) (2 trials)

sodium acetate (1 trial)

sodium chloride (3 trials)

sucroferric oxyhydroxide (velphoro) (1 trial)

triamcinolone (kenalog) (1 trial)

valproic acid (depakene) (1 trial)

venlafaxine (effexor) (1 trial)

zinc dichloride (1 trial)

Drugs in Phase 3 Trials (37)

aldoxorubicin (1 trial)

allogeneic stem cells (1 trial)

autologous hematopoietic cell (1 trial)

autologous mononuclear stem cell (1 trial)

busulfan (myleran) (2 trials)

cladribine (leustatin) (1 trial)

cyclophosphamide (cytoxan) (6 trials)

cyclosporine (sandimmune) (2 trials)

cytarabine (cytosar-u) (4 trials)

dactinomycin (cosmegen) (2 trials)

daunorubicin (cerubidine) (4 trials)

dexamethasone (2 trials)

doxorubicin (Doxil) (6 trials)

icosapent ethyl (vascepa) (1 trial)

idarubicin (idamycin) (1 trial)

l-alanyl-l-glutamine (1 trial)

lidocaine (xylocaine) (1 trial)

melphalan (alkeran) (1 trial)

mercaptopurine (purinethol) (1 trial)

mesna (mesnex) (1 trial)

methotrexate (2 trials)

pegaspargase (oncaspar) (1 trial)

prednisolone (hydeltra) (2 trials)

prednisone (meticorten) (3 trials)

pxt3003 (2 trials)

rituximab (rituxan) (2 trials)

sargramostim (leukine) (3 trials)

serlopitant (2 trials)

testosterone (delatestryl) (3 trials)

thalidomide (Thalomid) (1 trial)

tioguanine (Lanvis) (2 trials)

tresulfan (1 trial)

urea (2 trials)

vincristine (oncovin) (6 trials)

vindesine (2 trials)

voclosporin (Lupkynis) (1 trial)

zoledronic acid (zometa) (1 trial)

Drugs in Phase 2 Trials (22)

alitretinoin (panretin) (1 trial)

aminolevulinic acid (levulan) (3 trials)

amphotericin b (fungizone) (1 trial)

apalutamide (erleada) (1 trial)

azacitidine (vidaza) (1 trial)

azathioprine (imuran) (1 trial)

bupropion (wellbutrin) (1 trial)

caspofungin (cancidas) (1 trial)

cd19 car-t cells (1 trial)

copanlisib (aliqopa) (1 trial)

epoetin (Epogen) (1 trial)

fumaric acid esters (1 trial)

ibrutinib (imbruvica) (1 trial)

inotuzumab ozogamicin (besponsa) (1 trial)

isis 678354 (1 trial)

nintedanib (ofev) (1 trial)

o-(2[18f]fluoroethyl)-l-tyrosine (1 trial)

pazopanib (votrient) (1 trial)

pemetrexed (alimta) (1 trial)

pimecrolimus (elidel) (1 trial)

rmc-035 (1 trial)

sorafenib (nexavar) (2 trials)

Drugs in Phase 1 Trials (1)

truncated tissue factor (1 trial)

Drugs in Other Trials (4)

arginine (1 trial)

nimotuzumab (1 trial)

vitamin c (1 trial)

zinc sulfate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 4)

Alzheimer Disease (Phase 4)

Amyotrophic Lateral Sclerosis (Phase 2)

Anemia (Phase 4)

Aphasia (Phase 4)

Atherosclerosis (Phase 4)

Brain Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Charcot-Marie-Tooth Disease (Phase 3)

Cognitive Dysfunction (Phase 4)

Communicable Diseases (Phase 4)

Cross Infection (Phase 4)

Dementia (Phase 4)

Disease Progression (Phase 4)

Dissociative Disorders (Phase 4)

Dyslexia (Phase 4)

Glioblastoma (Phase 2)

Hemorrhage (Phase 4)

Hereditary Sensory and Motor Neuropathy (Phase 3)

Huntington Disease (Phase 2)

Hypogonadism (Phase 3)

Infections (Phase 4)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 4)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Lupus Erythematosus, Cutaneous (Phase 2)

Lupus Erythematosus, Systemic (Phase 2)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Non-Hodgkin (Phase 3)

Motor Neuron Disease (Phase 2)

Multiple Myeloma (Phase 3)

Multiple Sclerosis (Phase 4)

Multiple Sclerosis, Relapsing-Remitting (Phase 4)

Mycoses (Phase 2)

Neoplasms, Germ Cell and Embryonal (Phase 4)

Neoplasms, Plasma Cell (Phase 3)

Nerve Compression Syndromes (Phase 3)

Nerve Degeneration (Phase 4)

Neuroblastoma (Phase 2)

Neurodermatitis (Phase 3)

Osteoarthritis (Phase 4)

Pemphigoid, Bullous (Phase 2)

Periodontitis (Phase 4)

Pharyngitis (Phase 4)

Phobic Disorders (Phase 2)

Plaque, Atherosclerotic (Phase 4)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Prostatic Neoplasms (Phase 2)

Prurigo (Phase 3)

Pruritus (Phase 3)

Psoriasis (Phase 3)

Renal Insufficiency (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Retinal Detachment (Phase 4)

Sarcoma (Phase 3)

Sarcoma, Ewing (Phase 3)

Sclerosis (Phase 4)

Sjogren's Syndrome (Phase 1)

Staphylococcal Infections (Phase 4)

Stroke (Phase 4)

Syndrome (Phase 1)

Tooth Diseases (Phase 3)

Wilms Tumor (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 77
  • # of Trial APIs: 112